Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Pim Hermans"'
Autor:
Ana Sofia Moreira, Sandra Bezemer, Tiago Q. Faria, Frank Detmers, Pim Hermans, Laurens Sierkstra, Ana Sofia Coroadinha, Cristina Peixoto
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 4, p 3354 (2023)
The use of viral vectors as therapeutic products for multiple applications such as vaccines, cancer treatment, or gene therapies, has been growing exponentially. Therefore, improved manufacturing processes are needed to cope with the high number of f
Externí odkaz:
https://doaj.org/article/4b480447a65d46f5a817dc5d6bfa1d4e
Autor:
Farah Aladin, Alexandra W C Einerhand, Janneke Bouma, Sandra Bezemer, Pim Hermans, Danielle Wolvers, Kate Bellamy, Leon G J Frenken, Jim Gray, Miren Iturriza-Gómara
Publikováno v:
PLoS ONE, Vol 7, Iss 3, p e32949 (2012)
Rotavirus is the main cause of viral gastroenteritis in young children. Therefore, the development of inexpensive antiviral products for the prevention and/or treatment of rotavirus disease remains a priority. Previously we have shown that a recombin
Externí odkaz:
https://doaj.org/article/cfee33b3b4b74efe892dd4a8a635883e
Publikováno v:
Cell and Gene Therapy Insights. 4:101-111
Autor:
T. Stav-Noraas, T. Holt Herreng, S. Kjær, H. Almåsbak, K.E. Bernstroem, K. Alfsnes, E. Klijs, H. Adams, C. Wielders, Grethe Økern, D. Gjolberg, O. Amellem, Pim Hermans, J. de Rooij, L. Sierkstra
Publikováno v:
Cytotherapy. 23:S95
Autor:
Mafalda G. Moleirinho, Rita P. Fernandes, Cristina Peixoto, Ricardo Silva, Manuel J.T. Carrondo, Paula M. Alves, Sofia B. Carvalho, Pim Hermans, Sandra Bezemer, Frank Detmers
Publikováno v:
Separation and Purification Technology. 241:116693
The demand for new biopharmaceuticals has grown considerably in the last decade, with their use in applications such as vaccination, gene therapy and oncolytic therapy. However, their biological complexity brings new challenges for up- and downstream
Publikováno v:
Journal of molecular biology. 430(3)
Monoclonal antibodies constitute one of the largest groups of drugs to treat cancers and immune disorders, and are guiding the design of vaccines against infectious diseases. Fragments antigen-binding (Fabs) have been preferred over monoclonal antibo
Publikováno v:
Biotechnology Progress. 30:1311-1318
Antigen-binding fragments (Fabs) are novel formats in the growing pipeline of biotherapeutics. Sharing similar features to monoclonal antibodies (mAbs) with regard to expression, Fabs are considered as unchallenging for upstream development. Yet for
Autor:
Jing, Jin, Kathryn A, Hjerrild, Sarah E, Silk, Rebecca E, Brown, Geneviève M, Labbé, Jennifer M, Marshall, Katherine E, Wright, Sandra, Bezemer, Stine B, Clemmensen, Sumi, Biswas, Yuanyuan, Li, Aadil, El-Turabi, Alexander D, Douglas, Pim, Hermans, Frank J, Detmers, Willem A, de Jongh, Matthew K, Higgins, Rebecca, Ashfield, Simon J, Draper
Publikováno v:
International Journal for Parasitology
Graphical abstract
Highlights • Fusion of a four amino acid ‘C-tag’ allows purification of a PfRH5 malaria vaccine. • Overall process yield of 40–45% and very high product purity (>99%) was achieved. • His6-tagged and C-tagged PfRH5
Highlights • Fusion of a four amino acid ‘C-tag’ allows purification of a PfRH5 malaria vaccine. • Overall process yield of 40–45% and very high product purity (>99%) was achieved. • His6-tagged and C-tagged PfRH5
Autor:
Timothy M, Pabst, Michaela, Wendeler, Xiangyang, Wang, Sandra, Bezemer, Pim, Hermans, Alan K, Hunter
Publikováno v:
Biotechnology Journal
Interest in new and diverse classes of molecules such as recombinant toxins, enzymes, and blood factors continues to grow for use a biotherapeutics. Compared to monoclonal antibodies, these novel drugs typically lack a commercially available affinity
Autor:
Kevin Sleijpen, Marc H. De Baets, Maartje G. Huijbers, Rinse Klooster, Kirsten R. Straasheijm, Silvère M. van der Maarel, Jaap J. Plomp, Jan J.G.M. Verschuuren, Frank Detmers, Aad Verrips, Erik H. Niks, Pilar Martinez-Martinez, Mario Losen, Pim Hermans
Publikováno v:
Brain, 135, 1081-101
Brain, 135, Pt 4, pp. 1081-101
Brain, 135, 1081-1101. Oxford University Press
BRAIN, 135, 1081-1101
Brain, 135, 1081-1101
Brain, 135, Pt 4, pp. 1081-101
Brain, 135, 1081-1101. Oxford University Press
BRAIN, 135, 1081-1101
Brain, 135, 1081-1101
Item does not contain fulltext Myasthenia gravis is a paralytic disorder with autoantibodies against acetylcholine receptors at the neuromuscular junction. A proportion of patients instead has antibodies against muscle-specific kinase, a protein esse